ArticleBlood advances2022

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.

Gareth P Gregory et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.